Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection

Labò, Nazzarena; Ohnuki, Hidetaka; Tosato, Giovanna

doi:10.3390/cells9071583

Cited by 76 publications

(92 citation statements)

References 230 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 One of the theories that appear to have been playing a role is the selectivity of coronavirus toward angiotensin-converting enzyme 2 (ACE2) receptors. 7 On binding to cell surface ACE2 receptors, it inhibits the vaso-protective functions of ACE, causing pro-inflammatory and prothrombotic states. In addition, the systemic increase of pro-inflammatory cytokines such as interleukin-6 is also believed to be a major contributor of inducing hypercoagulable state in COVID-19.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the systemic increase of pro-inflammatory cytokines such as interleukin-6 is also believed to be a major contributor of inducing hypercoagulable state in COVID-19. Furthermore, COVID-19 compromises the integrity of endothelial monolayer by causing endothelial cell death through its lytic replication, 7 thus exposing the thrombogenic basement membrane and in turn leading to the activation of coagulation cascade. 7 Acknowledging that SARS-CoV-2 leads to a hypercoagulable state, the role of anticoagulation is important.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, COVID-19 compromises the integrity of endothelial monolayer by causing endothelial cell death through its lytic replication, 7 thus exposing the thrombogenic basement membrane and in turn leading to the activation of coagulation cascade. 7 Acknowledging that SARS-CoV-2 leads to a hypercoagulable state, the role of anticoagulation is important. As per Klok et al, 8 the incidence of thrombotic complications in critically ill patients in intensive care unit is 31%.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient

Harsh

Iyer

Zaghlol

et al. 2021

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient

Harsh

Iyer

Zaghlol

et al. 2021

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

“…The cardiovascular complications of COVID-19 have drawn more attention from both clinicians and investigators, although the exact mechanism for the myocardial injuries caused by SARS-CoV-2 is not completely understood [ 89 – 91 ]. Recently, new clinical syndromes associated with coagulopathy and vasculopathy have emerged as a cause of sudden death and other serious clinical manifestations in younger COVID-19 patients [ 90 ]. Angiotensin-converting enzyme 2 (ACE2), the receptor for SARS-CoV-2 and other coronaviruses, is a transmembrane protein expressed by lung alveolar epithelial cells, enterocytes, and vascular endothelial cells whose physiological role is to induce the maturation of angiotensin I to generate angiotensin 1-7, a peptide hormone that controls vasoconstriction and blood pressure [ 92 , 93 ].…”

Section: Sars-cov-2-induced Cardiovascular Injuriesmentioning

confidence: 99%

Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives

Zhang

et al. 2020

Acta Pharmacol Sin

View full text Add to dashboard Cite

The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients. Therefore, chloroquine phosphate was first used in the treatment of COVID-19 in China. Later, under a limited emergency-use authorization from the FDA, hydroxychloroquine in combination with azithromycin was used to treat COVID-19 patients in the USA, although the mechanisms of the anti-COVID-19 effects remain unclear. Preliminary outcomes from clinical trials in several countries have generated controversial results. The desperation to control the pandemic overrode the concerns regarding the serious adverse effects of chloroquine derivatives and combination drugs, including lethal arrhythmias and cardiomyopathy. The risks of these treatments have become more complex as a result of findings that COVID-19 is actually a multisystem disease. While respiratory symptoms are the major clinical manifestations, cardiovascular abnormalities, including arrhythmias, myocarditis, heart failure, and ischemic stroke, have been reported in a significant number of COVID-19 patients. Patients with preexisting cardiovascular conditions (hypertension, arrhythmias, etc.) are at increased risk of severe COVID-19 and death. From pharmacological and cardiovascular perspectives, therefore, the treatment of COVID-19 with chloroquine and its derivatives should be systematically evaluated, and patients should be routinely monitored for cardiovascular conditions to prevent lethal adverse events.

show abstract

“…in a study of diabetic and obese patients with COVID-19, have suggested that serum amyloid may play a key role in the pathogenesis of COVID-19, in addition to potentially having a prognostic role. COVID-19 includes an evolving set of clinical manifestations, including stroke and cardiomyopathies associatedwith coagulopathy and vasculopathy, which can cause sudden death and other serious morbidities[71]. A study by Fogarty, et al[72] has shown that race and ethnicity have major effects upon thrombotic risk, with significantly lower risk in Chinese compared to Caucasian individuals.…”

mentioning

confidence: 99%

A Systematic Analysis of Laboratory-Guided Diagnosis and Management of Covid-19: Challenges and Recommendations

Whelan

Keaney

Lucey

et al. 2020

Journal of Diseases

View full text Add to dashboard Cite

We conducted a comprehensive analysis of patient demographics and laboratory tests encompassing Real Time PCR (RT-qPCR) and serology for SARS-CoV-2 in addition to blood components and clinical blood markers for COVID-19 disease. All relevant literature was included up to 15 July 2020 and multiple studies were analysed in tandem to correlate findings. For RT-qPCR, nasopharyngeal swabs are the most suitable samples based on detection rates by sample, but may require repeat testing. One-week post-symptom onset, serological testing is a more stable marker. Antibody titers have been linked to disease severity. Several clinical blood components and markers have been reported to be prognostically useful; however, care is needed when making interpretation owing to the association between raised levels of these being found for the co-morbidities that predispose to worse prognosis in COVID-19. Challenges in the current study when finding the information presented in this paper suggest the need for a quality assured database that outlines the complete set of results, anonymised patient data for each entry and a set of internationally-agreed guidelines for complete laboratory testing, documentation and open-access reporting. We suggest that such information would be useful to help with patient diagnosis and management, worldwide. Contribution/Originality: This review compiles a large set of data on the efficacy of different laboratory tests in predicting severity of sequelae post COVID-19 infection and it recommends that anonymized patient results might be added to an international database from the time a pandemic is announced to help with patient management, worldwide. 1. INTRODUCTION There have been significant pandemics already in the first two decades of the 21 st century. For example, by July 2003, the severe acute respiratory syndrome (SARS) pandemic had resulted in 8,096 reported cases, including 774 deaths in 27 countries [1]. Certain severe acute respiratory syndrome coronavirus (SARS-CoV)-like viruses found in bats have recently been shown to be able to infect human cells without adaptation, suggesting the potential for SARS to re-emerge [2]. In May 2015, a single person returning from the Middle East started a nosocomial outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) in South Korea that involved 16 hospitals and 186 patients [3]. By July 2017, 2,040 MERS-CoV laboratory-confirmed cases, resulting in 712 deaths, were reported globally.

show abstract

Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection

Cited by 76 publications

References 230 publications

Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient

Case Report: Multiple Strokes and Digital Ischemia in a Young COVID-19 Patient

Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives

A Systematic Analysis of Laboratory-Guided Diagnosis and Management of Covid-19: Challenges and Recommendations

Contact Info

Product

Resources

About